Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $1.09, $0.20 better than the analyst estimate of $0.89. Revenue for the quarter came in at $5.7 billion versus the consensus estimate of $5.64 billion.

“We had a very good quarter with strong commercial performance and advances in our portfolio through important clinical and regulatory milestones, including exciting new data for psoriasis patients with our internally discovered and developed TYK2 inhibitor,” said Giovanni Caforio, M.D., chairman and chief executive officer, Bristol-Myers Squibb. “Looking forward, we will continue to deliver on our strategy through robust commercial execution and advancing the potential of our increasingly diverse R&D pipeline.”

GUIDANCE:

Bristol-Myers Squibb sees FY2018 EPS of $3.80-$3.90, versus the consensus of $3.64.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.